Identification of biomarkers related to Tumor-Infiltrating Lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer

References

• Wittekind C, Compton CC, Greene FL, et al. TNM residual tumor classification revisited. Cancer. 2002;94(9):2511–2516.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Mason MJ, Sinicrope FA, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017;28(5):1023–1031.
   PubMed Web of Science ®Google Scholar
• Meyers BM, Cosby R, Quereshy F, et al. Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: a Cancer Care Ontario Systematic Review. Clin Oncol (R Coll Radiol). 2017;29(7):459–465.
   PubMed Web of Science ®Google Scholar
• Yazdanifar M, Barbarito G, Bertaina A, et al. gammadelta T Cells: the Ideal Tool for Cancer Immunotherapy. Cells. 2020;9(5):1305.
   Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.
   PubMed Web of Science ®Google Scholar
• Rong L, Li K, Li R, et al. Analysis of tumor-infiltrating gamma delta T cells in rectal cancer. World J Gastroenterol. 2016;22(13):3573–3580.
   PubMed Web of Science ®Google Scholar
• Silva-Santos B, Mensurado S, Coffelt SB. gammadelta T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat Rev Cancer. 2019;19(7):392–404.
   PubMed Web of Science ®Google Scholar
• Sebestyen Z, Prinz I, Dechanet-Merville J, et al. Translating gammadelta (gammadelta) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2020;19(3):169–184.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang C. The Role of Human gammadelta T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy. Cells. 2020;9(5):1206.
   Web of Science ®Google Scholar
• Uryvaev A, Passhak M, Hershkovits D, et al. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol. 2018;35(3):25.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
   PubMed Web of Science ®Google Scholar
• Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71(17):5670–5677.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Li J, Song S, et al. A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis. J Exp Clin Cancer Res. 2019;38(1):314.
   PubMedGoogle Scholar
• Conrad C, Gotte M, Schlomann U, et al. ADAM8 expression in breast cancer derived brain metastases: functional implications on MMP-9 expression and transendothelial migration in breast cancer cells. Int J Cancer.2018;142(4):779-791 .
   Google Scholar
• Romagnoli M, Mineva ND, Polmear M, et al. ADAM 8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Mol Med. 2014;6(2):278–294.
   PubMed Web of Science ®Google Scholar
• Dong F, Eibach M, Bartsch JW, et al. The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. Neuro Oncol. 2015;17(11):1474–1485.
   PubMed Web of Science ®Google Scholar
• Wildeboer D, Naus S, Amy Sang QX, et al. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol. 2006;65(5):516–527.
   PubMed Web of Science ®Google Scholar
• Huang J, Bai Y, Huo L, et al. Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer. Transl Res. 2015;166(6):602–613.
   PubMed Web of Science ®Google Scholar
• Schlomann U, Koller G, Conrad C, et al. ADAM8 as a drug target in pancreatic cancer. Nat Commun. 2015;6(1):6175.
   PubMedGoogle Scholar
• Zhang W, Wan M, Ma L, et al. Protective effects of ADAM8 against cisplatin-mediated apoptosis in non-small-cell lung cancer. Cell Biol Int. 2013;37(1):47–53.
   PubMed Web of Science ®Google Scholar
• Hernandez I, Moreno JL, Zandueta C, et al. Novel alternatively spliced ADAM8 isoforms contribute to the aggressive bone metastatic phenotype of lung cancer. Oncogene. 2010;29(26):3758–3769.
   PubMed Web of Science ®Google Scholar
• Yang Z, Bai Y, Huo L, et al. Expression of A disintegrin and metalloprotease 8 is associated with cell growth and poor survival in colorectal cancer. BMC Cancer. 2014;14(1):568.
   PubMedGoogle Scholar
• Miyauchi M, Koya J, Arai S, et al. ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells. Stem Cell Reports. 2018;10(3):1115–1130.
   PubMed Web of Science ®Google Scholar
• Li SQ, Wang DM, Zhu S, et al. The important role of ADAM8 in the progression of hepatocellular carcinoma induced by diethylnitrosamine in mice. Hum Exp Toxicol. 2015;34(11):1053–1072.
   PubMed Web of Science ®Google Scholar
• Uen YH, Fang CL, Hseu YC, et al. VAV3 oncogene expression in colorectal cancer: clinical aspects and functional characterization. Sci Rep. 2015;5(1):9360.
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar